BSX Form 4: EVP Fitzgerald acquires 50k, sells 50k; ownership falls to 178,342

Rhea-AI Filing Summary

Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported multiple transactions on 09/02/2025 effected under a pre-established Rule 10b5-1 trading plan adopted February 27, 2025. The report shows 50,000 shares acquired at a price of $26.15 (code M) and two dispositions totaling 50,000 shares sold in multiple trades at weighted average prices of $104.886 and $105.8486. After these transactions, the reporting person beneficially owned 178,342 shares directly, with an additional 5,234 shares held indirectly by his child which he disclaims beneficial ownership of. The filing includes an option related entry reflecting a 50,000-share option with the same $26.15 figure and references vesting in four equal annual installments beginning December 1, 2018.

The form is signed by an attorney-in-fact on behalf of the reporting person and discloses the reporting person will provide detailed per-price sale breakdowns upon request by the SEC or others.

Positive

• Transactions executed under a pre-established Rule 10b5-1 plan, indicating an affirmative defense for planned trades
• Detailed disclosure including weighted average sale prices and a willingness to provide per-price sale breakdowns upon request
• Attorney-in-fact signature present, demonstrating formal execution of the filing

Negative

• Insider sold a total of 50,000 shares on 09/02/2025, reducing direct beneficial ownership from 228,342 to 178,342 shares
• Significant share sales at prices (~$105) materially above the $26.15 exercise/reference price, which changes the insider's direct ownership stake

Insights

Securities Analyst

TL;DR: Insider executed matched option/stock transactions under a 10b5-1 plan, resulting in net direct holdings of 178,342 shares.

The filing documents contemporaneous option-related activity and share sales executed pursuant to a Rule 10b5-1 plan adopted Feb 27, 2025. The reporting person acquired 50,000 shares at $26.15 and sold 50,000 shares in separate trades at weighted average prices of $104.886 and $105.8486. These transactions reduced direct beneficial ownership to 178,342 shares while 5,234 shares are reported as held by a child and disclaimed. The filing is routine in form and provides transparency by committing to disclose per-price sale details upon request.

Corporate Governance Expert

TL;DR: Transactions were executed under a pre-established trading plan, reflecting compliance with insider-trading frameworks.

The disclosure confirms the use of a written 10b5-1 plan and includes an attorney-in-fact signature, indicating procedural compliance. The report also explicitly disclaims beneficial ownership of shares held by the reporting person’s child. The presence of the plan and the commitment to provide detailed sale price breakdowns on request supports robust disclosure practices for insider activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Joseph Michael

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Group Pres, Cardiology

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		M(1)		50,000	A	$26.15	228,342	D
Common Stock	09/02/2025		S(1)		21,830	D	$104.886(2)	206,512	D
Common Stock	09/02/2025		S(1)		28,170	D	$105.8486(3)	178,342	D
Common Stock								5,234(4)	I	By Child

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.15	09/02/2025		M(1)			50,000	(5)	12/01/2027	Common Stock	50,000	$0.0000	100,000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.32 to $105.25 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.32 to $106.27, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

5. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Boston Scientific insider Joseph Michael Fitzgerald report on Form 4 (BSX)?

The filing reports 50,000 shares acquired at $26.15 and two dispositions totaling 50,000 shares sold at weighted average prices of $104.886 and $105.8486 on 09/02/2025.

Were the trades by the BSX insider part of a 10b5-1 plan?

Yes. The transactions were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

How many Boston Scientific shares does the reporting person beneficially own after these transactions?

Following the reported transactions the reporting person beneficially owned 178,342 shares directly, and 5,234 shares are reported as held by his child (disclaimed).

Does the Form 4 provide detailed sale price breakdowns for the share disposals?

The Form 4 provides weighted average prices and states the reporting person will provide full information on the number of shares sold at each separate price upon request by the SEC, the issuer, or a security holder.

Who signed the Form 4 for the reporting person?

The Form 4 is signed by /s/ Susan Thompson, Attorney-in-Fact on 09/03/2025.